A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
Completed · Phase 1
Conditions studied: Wheezing, Reactive Airway Disease, Mild Asthma
In brief
The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease or mild asthma using a nebulizer, the VR647 Inhalation System. Secondary objectives include the evaluation of the safety and tolerability of VR647 Inhalation Suspension administered using the VR647 Inhalation System. The study consists of four visits; a screening visit (Visit 1), two dosing days (Visits 2 and 3) and a follow-up visit (Visit 4). On each dosing day a single dose of treatment will be administered. Treatment allocation at Visits 2 and 3 is determined by a balanced incomplete block design.
Key facts
- Study ID
- NCT03421730
- Run by
- Vectura Limited
- People needed
- 17
- Starts
- 2017-12-18
- Expected to finish
- 2018-03-27
- Last updated by the study team
- 2019-10-21
Who can join
Age: 4 and older, up to 8. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Vectura Study Site 0003 — Colorado Springs, Colorado, United States
- Vectura Study Site 0002 — Raleigh, North Carolina, United States
- Vectura Study Site 0001 — Tulsa, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.